查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1589797

勃起功能障碍药物市场：按药物、给药方法、分销管道分类 - 全球预测 2025-2030

Erectile Dysfunction Drugs Market by Drug (Avanafil (Stendra), Muse Suppository (Alprostadil), Sildenafil (Viagra)), Mode of Administration (Injections, Oral, Topical), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年勃起功能障碍药物市场价值为24.1亿美元，预计到2024年将达到25.9亿美元，复合年增长率为7.41%，预计到2030年将达到39.8亿美元。

勃起功能障碍 (ED) 药物的市场范围包括旨在治疗男性 ED 的药物，ED 的定义是无法获得或维持足以进行性交的勃起。此类别包括但不限于 5 型磷酸二酯酶抑制剂，例如Sildenafil（威而钢）、他达拉非（犀利士）和伐地那非（艾力达）。人口老化、糖尿病和心血管疾病等慢性疾病的增加，以及压力和肥胖等生活方式因素影响的 ED 盛行率的增加，推动了对此类药物的需求。最终用途部分包括使用或开立这些药物的医院、诊所和家庭护理机构。

主要市场统计
基准年[2023] 24.1亿美元
预测年份 [2024] 25.9亿美元
预测年份 [2030] 39.8亿美元
复合年增长率（%） 7.41%

市场成长受到诸如 ED 作为医疗状况的认识和接受程度提高、药物配方的进步以及临床试验中强大的治疗药物管道等因素的影响。新的治疗机会在于开发副作用较少的下一代治疗剂、开髮长效製剂以及开发局部应用和注射等肠胃外给药系统。新兴国家的潜在成长进一步加剧了这种情况，这些国家生活方式的改变增加了 ED 的发病率，使其成为一个开拓的市场。

然而，存在一些限制和挑战，例如严格的监管要求、潜在的副作用以及草药补充品和真空勃起装置等替代疗法的存在，这些可能会影响药物干预措施的市场渗透。创新和研究机会包括探索个人化医疗方法，例如 ED 治疗反应性的遗传标记以及远端医疗与患者诊断和处方服务的整合。了解市场动态需要识别影响患者接受治疗意愿的障碍，例如 ED 耻辱感。总体而言，透过专注于研发、策略伙伴关係和推广计划，市场参与者可以利用这些趋势并实现永续成长。

市场动态：揭示快速发展的勃起功能障碍药物市场的关键市场洞察

供需的动态交互作用正在改变勃起功能障碍药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 老年族群中勃起功能障碍患者数量不断增加
    • 久坐的生活方式和文明病的发生率增加
    • 非学名药的普及和OTC ED药物的获取便利性
  • 市场限制因素
    • 与勃起功能障碍药物相关的副作用
  • 市场机会
    • ED 药物的进步和新产品上市数量的增加
    • 研究和发展的重点是开发勃起功能障碍的有效治疗方法
  • 市场挑战
    • 具有成本效益的假药的可用性

波特五力：驾驭勃起功能障碍药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解勃起功能障碍药物市场的外部影响

外部宏观环境因素在塑造勃起功能障碍治疗药物市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解勃起功能障碍治疗药物市场的竞争状况

勃起功能障碍药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来发现自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV 定位矩阵勃起功能障碍治疗药物市场供应商的绩效评估

FPNV 定位矩阵是评估勃起功能障碍治疗药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製勃起功能障碍治疗药物市场的成功之路

对于希望加强在全球市场的影响力的公司来说，勃起功能障碍药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 老年人勃起功能障碍增加
      • 久坐的生活方式和文明病的发生率增加
      • 非学名药的普及和非处方 ED 治疗的便利性
    • 抑制因素
      • 与勃起功能障碍药物相关的副作用
    • 机会
      • ED 治疗药物的进步和新产品的推出不断增加
      • 研究和开发的重点是开发有效的治疗方法和治疗勃起功能障碍的方法
    • 任务
      • 具有成本效益的假药的可用性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 勃起功能障碍治疗药物市场（依药物）

  • 阿伐那非（Stendra）
  • Muse栓剂（Alprostadil）
  • Sildenafil（威而钢）
  • 他达拉非（犀利士）
  • 伐地那非（艾力达，Staxyn）

第七章依管理方式分類的勃起功能障碍治疗药物市场

  • 注射
  • 口服
  • 话题

第八章勃起功能障碍治疗药物市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第九章北美和南美的勃起功能障碍药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区勃起功能障碍药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的勃起功能障碍药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Adamed Sp. z oo
  • Bayer AG
  • Cipla Limited
  • Dr. Reddys Laboratories Ltd.
  • Eli Lilly and Company
  • Endo International PLC
  • Futura Medical PLC
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Novartis International AG
  • Pfizer Inc.
  • SK Chemicals Co. Ltd.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vivus, Inc.
Product Code: MRR-4348D129FAF4

The Erectile Dysfunction Drugs Market was valued at USD 2.41 billion in 2023, expected to reach USD 2.59 billion in 2024, and is projected to grow at a CAGR of 7.41%, to USD 3.98 billion by 2030.

The market scope for erectile dysfunction (ED) drugs encompasses pharmaceuticals aimed at treating males with ED, a condition defined as the persistent inability to achieve or maintain an erection sufficient for sexual intercourse. This category includes but is not limited to phosphodiesterase type 5 inhibitors like sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra). The necessity for such medications is driven by the increasing prevalence of ED, influenced by aging populations, rising chronic health conditions like diabetes and cardiovascular diseases, and lifestyle factors such as stress and obesity. Applications primarily revolve around enhancing erectile function to improve patient quality of life, while end-use segments include hospitals, clinics, and home care settings where these drugs are administered or prescribed.

KEY MARKET STATISTICS
Base Year [2023] USD 2.41 billion
Estimated Year [2024] USD 2.59 billion
Forecast Year [2030] USD 3.98 billion
CAGR (%) 7.41%

Market growth is influenced by factors such as increased awareness and acceptance of ED as a medical condition, advancements in drug formulations, and a robust pipeline of therapies under clinical trials. Emerging opportunities lie in developing next-generation treatment options with fewer side effects, long-acting formulations, and non-oral delivery systems, such as topical applications or injections. The landscape is further expanding with potential growth in emerging economies where lifestyle pattern shifts lead to higher ED incidence rates, representing untapped markets.

However, limitations and challenges include strict regulatory requirements, potential side effects, and the presence of alternative therapies such as herbal supplements or vacuum erectile devices, which may affect the market uptake of pharmaceutical interventions. Innovation and research opportunities exist in exploring personalized medicine approaches, such as genetic markers for ED treatment responsiveness, and the integration of telemedicine in patient diagnosis and prescription services to enhance reach and adherence. Understanding market dynamics requires identifying barriers like stigmatization of ED, which affects patient willingness to seek treatment. Overall, a keen focus on R&D, strategic partnerships, and outreach programs can help market players capitalize on these trends for sustained growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Erectile Dysfunction Drugs Market

The Erectile Dysfunction Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase cases of erectile dysfunction among geriatric population
    • Rising adoption of a sedentary lifestyle and incidence of lifestyle diseases
    • Prevalence of non generic drugs and easy availability of OTC ED drugs
  • Market Restraints
    • Side effects associated with the erectile dysfunction drugs
  • Market Opportunities
    • Increasing advancements and new product launches of ED drugs
    • R&D focused on developments of effective therapies and treatments for erectile dysfunction
  • Market Challenges
    • Availability of cost-effective counterfeit drugs

Porter's Five Forces: A Strategic Tool for Navigating the Erectile Dysfunction Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Erectile Dysfunction Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Erectile Dysfunction Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Erectile Dysfunction Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Erectile Dysfunction Drugs Market

A detailed market share analysis in the Erectile Dysfunction Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Erectile Dysfunction Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Erectile Dysfunction Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Erectile Dysfunction Drugs Market

A strategic analysis of the Erectile Dysfunction Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Erectile Dysfunction Drugs Market, highlighting leading vendors and their innovative profiles. These include Adamed Sp. z o.o., Bayer AG, Cipla Limited, Dr. Reddys Laboratories Ltd., Eli Lilly and Company, Endo International PLC, Futura Medical PLC, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Novartis International AG, Pfizer Inc., S.K. Chemicals Co. Ltd., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Vivus, Inc..

Market Segmentation & Coverage

This research report categorizes the Erectile Dysfunction Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug, market is studied across Avanafil (Stendra), Muse Suppository (Alprostadil), Sildenafil (Viagra), Tadalafil (Cialis), and Vardenafil (Levitra, Staxyn).
  • Based on Mode of Administration, market is studied across Injections, Oral, and Topical.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase cases of erectile dysfunction among geriatric population
      • 5.1.1.2. Rising adoption of a sedentary lifestyle and incidence of lifestyle diseases
      • 5.1.1.3. Prevalence of non generic drugs and easy availability of OTC ED drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects associated with the erectile dysfunction drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing advancements and new product launches of ED drugs
      • 5.1.3.2. R&D focused on developments of effective therapies and treatments for erectile dysfunction
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of cost-effective counterfeit drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Erectile Dysfunction Drugs Market, by Drug

  • 6.1. Introduction
  • 6.2. Avanafil (Stendra)
  • 6.3. Muse Suppository (Alprostadil)
  • 6.4. Sildenafil (Viagra)
  • 6.5. Tadalafil (Cialis)
  • 6.6. Vardenafil (Levitra, Staxyn)

7. Erectile Dysfunction Drugs Market, by Mode of Administration

  • 7.1. Introduction
  • 7.2. Injections
  • 7.3. Oral
  • 7.4. Topical

8. Erectile Dysfunction Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Erectile Dysfunction Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Erectile Dysfunction Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Erectile Dysfunction Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Adamed Sp. z o.o.
  • 2. Bayer AG
  • 3. Cipla Limited
  • 4. Dr. Reddys Laboratories Ltd.
  • 5. Eli Lilly and Company
  • 6. Endo International PLC
  • 7. Futura Medical PLC
  • 8. GlaxoSmithKline PLC
  • 9. Johnson & Johnson Services, Inc.
  • 10. Novartis International AG
  • 11. Pfizer Inc.
  • 12. S.K. Chemicals Co. Ltd.
  • 13. Sanofi S.A.
  • 14. Sun Pharmaceutical Industries Ltd.
  • 15. Teva Pharmaceutical Industries Ltd.
  • 16. Vivus, Inc.

LIST OF FIGURES

  • FIGURE 1. ERECTILE DYSFUNCTION DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ERECTILE DYSFUNCTION DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ERECTILE DYSFUNCTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ERECTILE DYSFUNCTION DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ERECTILE DYSFUNCTION DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY AVANAFIL (STENDRA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MUSE SUPPOSITORY (ALPROSTADIL), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY SILDENAFIL (VIAGRA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TADALAFIL (CIALIS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY VARDENAFIL (LEVITRA, STAXYN), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM ERECTILE DYSFUNCTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. ERECTILE DYSFUNCTION DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. ERECTILE DYSFUNCTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2023